Hôpital d'Instruction des Armées Begin

The department focuses on advanced pancreatic ductal adenocarcinoma. This work falls within the broader field of digestive system diseases. Ongoing studies aim to improve survival by testing new chemotherapy combinations and exploring the role of gut microbiota.

• Evaluation of a novel chemotherapy regimen with maintenance therapy
• Investigation of antibiotic adjuncts to enhance treatment response
• Analysis of microbiome influence on drug efficacy

Hôpital d'Instruction des Armées Begin collaborates with national oncology groups to bring innovative options to patients.

Research also targets patients who have undergone surgery for pancreatic adenocarcinoma. The goal is to personalize adjuvant therapy based on pathological findings.

• Risk‑adapted chemotherapy guided by tumor staging
• Comparison of standard adjuvant regimen versus pathology‑driven approach
• Long‑term outcomes such as disease‑free and overall survival

The site leverages its expertise in hepatogastroenterology to refine post‑operative care and improve cure rates.